Hormone Replacement Therapy for Surgical Menopause

Introduction to Hormone Replacement Therapy

The American College of Obstetricians and Gynecologists recommends hormone replacement therapy should be initiated immediately post-surgery and continued at least until age 51 for a 40-year-old woman with surgical menopause, then reassessed 1

Transdermal estradiol patches are the preferred first-line treatment, as they bypass hepatic first-pass metabolism and demonstrate superior cardiovascular and thrombotic risk profiles compared to oral formulations, according to the North American Menopause Society 1
The initial dose of estradiol patches should be 50 μg daily, applied twice weekly, as recommended by the Endocrine Society 1
Ultra-low-dose options, such as 14 μg/day, are available if standard doses cause side effects, as suggested by the American College of Obstetricians and Gynecologists 1

If the uterus is intact, micronized progesterone 200 mg orally at bedtime is the first choice, with lower rates of venous thromboembolism and breast cancer risk compared to synthetic progestins, according to the Society for Menopause Research 1
Alternative progestin options include combined estradiol/progestin patches or medroxyprogesterone acetate, as recommended by the North American Menopause Society 1

Hormone replacement therapy reduces vasomotor symptom frequency by 75%, according to the American College of Obstetricians and Gynecologists 1
Hormone replacement therapy reduces non-vertebral fractures by 27%, as reported by the National Osteoporosis Foundation 1
Hormone replacement therapy prevents accelerated bone loss, with a 2% annual loss in the first 5 years post-menopause, according to the Endocrine Society 1
Early initiation of hormone replacement therapy provides cardiovascular protection, as recommended by the American Heart Association 1

Absolute contraindications to hormone replacement therapy include history of breast cancer or hormone-sensitive malignancies, active or history of venous thromboembolism or stroke, coronary heart disease or myocardial infarction, active liver disease, antiphospholipid syndrome, and thrombophilic disorders, as listed by the American College of Obstetricians and Gynecologists 1, 2

Annual clinical review is recommended, focusing on compliance, ongoing symptom burden, and development of any contraindications, according to the North American Menopause Society 1
Hormone replacement therapy should be continued at least until age 51, then reassessed, as recommended by the Endocrine Society 1
No routine laboratory monitoring of estradiol levels is required, but mammography and bone density assessment should be performed according to standard screening guidelines, as suggested by the American College of Radiology and the National Osteoporosis Foundation 1, 3